Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- NDA for Lurasidone for Schizophrenia Accepted by FDA: DSP
March 29, 2010
- Febuxostat Launched in Europe: Teijin
March 29, 2010
- NDA for Bendamustine Submitted in Taiwan: SymBio
March 29, 2010
- Quintiles Relocates Its Global Central Lab in Japan to Tokyo
March 29, 2010
- Dry AMD Treatment ACU-4429 Receives Fast-Track Designation from the FDA: Otsuka, Acucela
March 29, 2010
- Symbicort Ranked No. 1 on GP Market
March 22, 2010
- WG to Be Created to Increase Self-Sufficiency Rate for Blood Products
March 22, 2010
- Booz & Company Proposes New Contract Manufacturing Business Model
March 22, 2010
- JMA Strongly Opposed to Promotion of “Integrated Medicine”
March 22, 2010
- Ajinomoto Pharm. to Set Out in April
March 22, 2010
- Vaccine-Related Societies to Create Consortium to Deal with Korosho
March 22, 2010
- Korosho Completes Hearings of Dispensing Pharmacy Chain Operators
March 22, 2010
- Requirements for High-Risk Drug Premium Explained by Korosho
March 22, 2010
- New Premium for Development of New Drugs “Poison Bait”
March 22, 2010
- Shionogi to Comarket Quick Chaser Flu A, B with Mizuho Medy
March 22, 2010
- Santen Files NDA for Higher-Concentration Levofloxacin
March 22, 2010
- Leading Generics-Only Companies'Foothold Undermined by Entry of Big Pharmas
March 22, 2010
- CDFS's Dept. on Drugs to Review Rozerem, DE-089, Soliris
March 22, 2010
- ¥105 Bil. Sales of Aricept to Be Lost in 3 Years Following Patent Expiration in the US
March 22, 2010
- 5-Day Dosing Regimen Approved for Dacogen in the US: Eisai
March 22, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…